Irene Haralabatos, MD
Allergy & Immunology · Philadelphia, PANPI 1386792430
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 543 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,912 and has fallen 86.6% since, to $257 in 2025.
Across 543 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Optinose US, Inc.$865
- Takeda Pharmaceuticals U.S.A., Inc.$752
- Sanofi$728
- CSL Behring$642
- plus $3K from 24 others
What the payments were for
- Food & beverage$9,33399%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 118 | $1,965 |
| AstraZeneca | 70 | $1,322 |
| Optinose US, Inc. | 59 | $865 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $752 |
| Sanofi | 42 | $728 |
| CSL Behring | 36 | $642 |
| Regeneron Healthcare Solutions, Inc. | 38 | $630 |
| Kaleo, Inc. | 22 | $396 |
| Biocryst US Sales Co., LLC | 13 | $285 |
| Pfizer | 22 | $281 |
| Novartis | 17 | $256 |
| Genentech USA, Inc. | 12 | $217 |
| Boehringer Ingelheim | 9 | $200 |
| Blueprint Medicines Corporation | 5 | $126 |
| Teva Pharmaceuticals USA, Inc. | 6 | $97 |
| Shire North American Group Inc | 5 | $87 |
| Grifols USA, LLC | 3 | $85 |
| Amgen | 4 | $72 |
| Bio Products Laboratory USA, Inc. | 5 | $71 |
| Covis Pharma GmbH | 4 | $52 |
| Merck | 3 | $45 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $43 |
| Aytu Biopharma, Inc. | 2 | $40 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Eyevance Pharmaceuticals LLC | 2 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Octapharma USA, Inc. | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Organon | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
How this compares
$9,412 in reported general payments places this provider in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $93,065 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $84,048 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $83,403 |
| Dupixent SyringeDupilumab | 11 | $40,999 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $37,599 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $37,533 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $29,820 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 70 | $21,793 |
| Arnuity ElliptaFluticasone Furoate | 42 | $12,983 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $11,494 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 189 | $9,409 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $7,227 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,410 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,431 |
| Epinephrine | 27 | $4,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,965 | $133,918161 claims |
| CSL BehringHizentra | $642 | $93,06513 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $71 | $84,04812 claims |
| Grifols USA, LLCGamunex-C | $85 | $37,59913 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $97 | $7,22711 claims |
| AstraZenecaSymbicort | $1,322 | $6,41018 claims |
| Hikma Pharmaceuticals USAEpinephrine | $28 | $4,45227 claims |
| Covis Pharma GmbHAlvesco | $52 | $2,81811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Philadelphia
- Drew WeissmanPhiladelphia$12.8M
- Arnold LevinsonPhiladelphia$95K
- Elias AklPhiladelphia$80K
- Neha SirohiPhiladelphia$62K
- John BossoPhiladelphia$42K
- Marc GoldsteinPhiladelphia$22K
- Raquel EmpedradPhiladelphia$21K
- Karin Flynn-RoddenPhiladelphia$15K
- Donald DvorinPhiladelphia$10K
- Juen KimPhiladelphia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.